Klaude S, Fruhauf L, Michels B, Malkowski JP, Helm EB, Althoff PH; International Conference on AIDS.

Int Conf AIDS. 1996 Jul 7-12; 11: 121 (abstract no. Mo.B.1384).

Klinikum der J.W.Goethe-Universitat, ZIM/Infektiologie, Frankfurt/Main, Germany. Fax: (49)-69-6301 5712.

Introduction: Wasting syndrome and weight loss are frequently observed in patients with HIV infection and can be seen in more than 50% of all patients with AIDS. Weight loss is associated with increased mortality, impaired physical functioning and quality of life. Wasting is a multifactorial event and characterised by loss of Lean Body Mass (LBM) with inappropriate preservation of fat, and endocrine disturbances are often found in such patients.Objective: To evaluate the efficacy of the anabolic active mammalian cell-derived recombinant human growth hormone (r-hGH[m], Serostim, Ares-Serono) in the treatment of HIV-associated wasting. Outcome parameters are changes in body weight (BW), body composition (LBM + Body Cell Mass (BCM), quality of life and safety.Methods: Daily administration of 6 mg r-hGH[m], s.c., for 12 weeks in HIV-infected male patients with CD4 less than 200/microliter and a minimum weight loss of 10% in 6 months, or a body weight less than 90% of the lower limit for ideal body weight. Absence of opportunistic infection (OI) or active malignancy. Body composition was determined using Bioelectrical Impedance Analysis (BIA).Results: 12 of 14 enrolled patients completed the 12 week follow-up. Two patients dropped out, (Day 4: due to oedema, nausea, headache, and Week 6: due to OI aspergillus pneumonia). 8/12 patients were considered treatment successes as they had a substantial increase (n = 5) in mean BW (6.4 plus or minus 1.6 kg), LBM (7.4 plus or minus 2.5 kg), BCM (4.6 plus or minus 1.5 kg) or stabilisation (n = 3) of previous severe wasting. 4/12 patients had a loss of BW. Conclusion: In about 70% of the patients a beneficial effect of treatment with r-hGH[m] (Serostim, Ares-Serono) was achieved by either increase of body weight, LBM and BCM or at least stabilisation of previous progressive wasting. The results therefore confirm r-hGH[m], as a promising treatment of HIV-associated wasting.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Antiretroviral Therapy, Highly Active
• Body Composition
• Body Weight
• Electric Impedance
• Endocrine System Diseases
• HIV Infections
• HIV Seropositivity
• HIV Wasting Syndrome
• Human Growth Hormone
• Humans
• Male
• Weight Loss
• drug therapy
• therapy

Other ID:

• 96921446

UI: 102217345

From Meeting Abstracts